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Abstract: Among marine organisms, sponges are the richest sources of pharmacologically-active
compounds. Stemming from a previous lead discovery program that gathered a comprehensive
library of organic extracts of marine sponges from the off-shore region of Portugal, crude extracts
of Erylus cf. deficiens collected in the Gorringe Bank (Atlantic Ocean) were tested in the innovative
high throughput screening (HTS) assay for inhibitors of indoleamine 2,3-dioxygenase (IDO) and
showed activity. Bioassay guided fractionation of the dichloromethane extract led to the isolation
of four new glycolipids, named erylusamide A–D. The structures of the isolated compounds
were established by 1D and 2D nuclear magnetic resonance (NMR) spectroscopy, high-resolution
electrospray ionization mass spectrometry (HR-ESI-MS) and chemical derivatization. The metabolites
shared a pentasaccharide moiety constituted by unusual highly acetylated D-glucose moieties as well
as D-xylose and D-galactose. The aglycones were unprecedented long chain dihydroxyketo amides.
Erylusamides A, B and D differ in the length of the hydrocarbon chain, while erylusamide C is a
structural isomer of erylusamide B.
Keywords: Erylus; indoleamine 2,3 dioxygenase; glycolipids; marine natural products; sponges;
anti-cancer; erylusamides
1. Introduction
The secondary metabolites found in marine invertebrates represent a rich source of novel
chemical diversity for lead compounds, with sponges being the most prolific source of new molecules.
Between these structurally unique metabolites, glycolipids play an important role. Glycolipids belong
to the broad class of glycoconjugates and are characterized by having one or more monosaccharide
residues linked by a glycosidic bond to a hydrophobic moiety, such as an acylglycerol, a sphingoid,
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or a prenyl phosphate [1]. Glycolipids, including glycosphingolipids and gangliosides, are widely
found in marine invertebrates, especially in echinoderms (sea stars, sea cucumbers) and sponges,
and show a large variety of biological activities such as antitumor, immunomodulatory and nitric
oxide release-inhibiting activities [2].
Sponges of the genus Erylus Gray, 1867 (Tetractinellida, Geodiidae) were reported to produce
uncommon phospholipid methyl branched fatty and unusual glycolipids, some of which have
interesting pharmacological activities, such as anticancer and interleukin-6 (IL-6) receptor antagonists
(Table 1). The same type of glycolipids found in Pachymatisma johnstonias, a species that belongs to the
same family of Erylus, showed inhibitory activity of bacterial type III secretion [3].





















































































































R1 = CH2CH2CH3, R2 = H
Erylusamine B:
R1 = CH2CH(CH3)2, R2 = H
Erylusamine C:
R1 = CH2CH(CH3)2 R2 = Ac
Erylusamine D:





























































emerged as a key  target  in cancer  immunotherapy. Several  inhibitors have been  synthesized and 
proved  to  be  efficient,  alone  or  in  combination with  other  therapeutics. However,  by  2014,  the 
pipeline of IDO inhibitors comprised only four drug candidates: indoximod, epacadostat, NLG919 
and an IDO derived peptide [12]. Indoximod (D‐1‐methyl‐tryptophan) is being tested in combination 
with  other  drugs  in  several  phase  I  and  II  clinical  trials.  Epacadostat  (INCB024360),  an 
hydroxyamidine that targets and binds to IDO1 is now in several phase I and II clinical trials [13]. 
NLG919  is an  imidazoleisoindole derivative undergoing phase  I clinical  trials  in  the  treatment of 
recurrent advanced solid tumors alone or in combination with other drugs. After the human IDO1 


























R1 = Ac; R2 = (CH2)5N(CH3)2; R3 = H,
n = 8, m = 2
Erylusine:
R1 = Ac; R2 = (CH2)3NCH3(CH2)4N(CH3)2;
R3 = H, n = 8, m = 2
Erylusidine
R1 = H; R2 = (CH2)4NHC = NH(NH2);
R3 = COCH2CH(CH3)2,
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Crude extract showed inhibitory activity of bacterial type III secretion
NR: not reported.
Indoleami e 2,3-dioxygenase (IDO1), formerly know as IDO before the discovery of a econd
isoform, is the first and rat -limiting enzym n the oxidative degradation of the essential amino
acid tryptophan through the kynurenine pathway and plays a role in the control of infection and in
evasion of T-cell-mediated immune rejection [10]. It is believe that IDO1 inhibits the roliferation a d
differentiation of T c lls, whic are ensit ve to t degradation of trypt phan and ccumulation of it
catabolites. IDO1 is overexpressed in a variety of tumor cell types and acts against the T-cell attack,
thus facilitating the growth d survival of malignant cells [11]. For these reasons, IDO1 has e erged
as a key target in cancer immunotherapy. Several inhibit rs have been synthesized and proved t
be efficient, alone or in combinati n with oth r the peutics. However, by 2014, t pipeline of IDO
inhibitors comprised only four drug candi ates: indoximod, epacadostat, NLG919 and an IDO derived
peptide [12]. Indoximod (D-1-methyl-tryptophan) is being tested in combination with other drugs in
several phase I and II clinical trials. Epacadostat (INCB024360), an hydroxyamidine that targets and
binds to IDO1 is now in several phase I and II clinical trials [13]. NLG919 is an imidazoleisoindole
derivative undergoing phase I clinical trials in t e treatment of recurrent advanced solid tumors
alone or in c mbinati n with other drugs. After the uman IDO1 structure was determined by X-ray
crystallography in 2006, several synthetic inhibitors w re developed based on the st ucture of the
active-site [14]; however, to the best of our knowledge, no comprehensive screening of compounds
(or extracts) from marine origin was ever undertaken.
With that background in view, in a previous project, we have undertaken a comprehensive
screening of crude extracts of sponges from the Portuguese coast using the Blockade application
of GPS D2 High Throughput Screening (HTS) system that uses the human version of indoleamine
2,3-dioxygenase 1 (IDO1) as therapeutic target [15]. This paper describes the isolation and structure
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determination of four new glycolipids, named erylusamides A–D, compounds 1–4 (Figure 1), found in
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Within  the  scope  of  a  previous  drug  discovery  campaign,  a  comprehensive  library  of  185 
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1H  nuclear  magnetic  resonance  (NMR)  spectrum  of  fraction  2  (150  mg)  revealed  complex 
signals  belonging  to  sugar  components  between  δ  6.4  and  3.5  ppm,  together  with  aliphatic 
resonances,  due  to  a  lipid  moiety  in  the  upfield  region  of  the  spectrum,  thus  suggesting  the 
occurrence of a series of glycoconjugates. Hence, as a  first step  in  the structure elucidation of  the 
bioactive  components,  a methanolysis  reaction was  performed  on  an  aliquot  of  the mixture  to 
liberate  the  aglycone  from  the monosaccharide pool. Methyl  glycosides were  converted  into  the 
corresponding  trimethylsilyl  (TMS) derivatives  [16] and analysed by GC‐MS  in  comparison with 
authentic  standards. According  to  retention  time  and  characteristic MS  fragmentation  patterns, 
monosaccharide units were  identified as D‐xylose, D‐glucose and D‐galactose. On  the other hand, 
aglycones showed IR bands at 3349, 1740, 1701 and 1636 cm−1, suggesting the presence of hydroxyl, 
ester,  ketone  and  amide  functionalities,  which  were  confirmed  by  NMR  data.  Separation  of 
individual  components  was  achieved  by  RP‐HPLC  on  a  phenyl‐hexyl  column  (Phenomenex) 
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2. Results and Discussion
Within the scope of a previous drug discovery campaign, a comprehensive library of 185 organic
extracts of sponge specimens collected in several off-shore Portuguese locations (Berlengas, Azores
and Gorringe bank) was constructed. The extracts were screened as modulators of proteins involved
in cancer and neurodegenerative diseases using the Global Platform Screening for Drug Discovery
(GPS D2) technology developed by the Portuguese biotech company BIOALVO (Lisbon, Portugal),
which uses modified Saccharomyces cerevisiae strains designed to express specific targets involved in
diseases with a tremendous social and economic burden. BIOALVO’s BLOCKADE application, which
targets compounds able to inhibit the enzyme indoleamine 2,3 dioxygenase (IDO-1), was selected to
first test the extracts. Extracts were considered positive if they inhibited the growth of BLOCKADE
yeast >60% [15]. In the BLOCKADE screening, the dichloromethane extract of the marine sponge
Erylus cf. deficiens collected in the Gorringe Bank (Atlantic Ocean) tested positive at a concentration of
0.125 mg/mL. The activity of this extract was confirmed using an additional assay with African green
monkey kidney fibroblast COS7 cells transfected with IDO, revealing an IDO inhibitory activity of
80%. The organic extract was further separated by flash chromatography on C18 reverse phase silica
gel (RP-18) into eleven fractions, one of which (fraction 2) conserved the activity of the original extract,
inhibiting kynurenine production by 80% at the same concentration.
1H nuclear magnetic resonance (NMR) spectrum of fraction 2 (150 mg) revealed complex signals
belonging to sugar components between δ 6.4 and 3.5 ppm, together with aliphatic resonances, due to
a lipid moiety in the upfield region of the spectrum, thus suggesting the occurrence of a series of
glycoconjugates. Hence, as a first step in the structure elucidation of the bioactive components, a
methanolysis reaction was performed on an aliquot of the mixture to liberate the aglycone from
the monosaccharide pool. Methyl glycosides were converted into the corresponding trimethylsilyl
(TMS) derivatives [16] and analysed by GC-MS in comparison with authentic standards. According to
retention time and characteristic MS fragmentation patterns, monosaccharide units were identified as
D-xylose, D-glucose and D-galactose. On the other hand, aglycones showed IR bands at 3349, 1740,
1701 and 1636 cm−1, suggesting the presence of hydroxyl, ester, ketone and amide functionalities,
which were confirmed by NMR data. Separation of individual components was achieved by RP-HPLC
on a phenyl-hexyl column (Phenomenex) affording 1–4 (Figure 1), as pure compounds, here named
erylusamides A–D. High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) analysis
in negative ionization polarity revealed that compounds 1–4 constituted a series of homologous
compounds displaying molecular mass ions at m/z 1782.8345, 1796.8515, 1796.8434 and 180.8644.
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Erylusamide A (1) gave a molecular ion [M − H]− at m/z 1782.8345, which accounts for the
molecular formula C83H133NO40 requiring 18 degrees of formal unsaturation. 1D and 2D-NMR
data (Tables 2 and 3) revealed diagnostic signals of an oligosaccharide moiety composed of five
sugar residues, and of a polyketide aglycone displaying three carbonyl signals at δ 210.5, 174.9 and
173.2 ppm in the 13C NMR spectrum. Several different spin systems were identified in the aglycone
moiety through COSY and HSQC-TOCSY connectivities, and joined by HMBC correlations (Figure 2).
In particular, one terminal end of the aglycone polyketide chain was assigned to a N-methylalanine
substructure. In fact, a deshielded signal at δ 5.75 (H-2′, q) was coupled in the COSY spectra with
a methyl doublet at δ 1.54 (H3-4′), as well as in the HMBC spectra, and showed correlations with
a carboxyl function at δ 174.9 ppm (C-1′) and a methyl carbon on a nitrogen atom at δ 31.5 ppm
(C-3′). In turn, the corresponding proton of this later signal was coupled to the carbonyl group at
δ 173.2 ppm. The N-methylalanine moiety displayed two sets of signals (ratio 3:1) in 1H NMR spectrum
of 1, consistent with a syn/anti rotamer equilibrium typically observed with tertiary amides [17],
the major conformer being the syn one as deducted from the NOESY correlation H-2 and H-3′. Indeed,
this phenomenon was also observed for structurally related pachymoside A, a glycolipid isolated from
the marine sponge Pachymatisma johnstonia [3].
Table 2. NMR data for the aglycone a moieties of erylusamides A–D (1–4) in pyridine-d5.
1 2 3 4
N◦ δ 13C δ
1H, m
(J, Hz)
N◦ δ 13C δ
1H, m
(J, Hz)
N◦ δ 13C δ
1H, m
(J, Hz)




173.2 - 1 173.2 - 1 173.2 - 1 173.2 -
173.1 - 173.1 - 173.1 - 173.1 -
2 33.8 2.43, m 2 33.8 2.43, m 2 33.8 2.43, m 2 33.8 2.43, m
3 25.5 1.81, m 3 25.5 1.81, m 3 25.5 1.81, m 3 25.5 1.82, m
4 29.7 1.38, m 4 29.8 1.38, m 4 29.8 1.39, m 4 29.7 1.38, m







13 29.6 1.28, m 13 29.6 1.28, m 13 29.6 1.28, m 13 29.6 1.28, m
14 24.2 1.64, m 14 24.2 1.64, m 14 24.2 1.64, m 14 24.2 1.65, m
15 42.8 2.42, m 15 42.7 2.42, m 15 42.8 2.42, m 15 42.8 2.42, m
16 210.5 - 16 210.5 - 16 210.5 - 16 210.5 -
17 42.8 2.42, m 17 42.7 2.42, m 17 42.8 2.42, m 17 42.8 2.42, m
18 24.2 1.64, m 18 24.2 1.64, m 18 24.2 1.64, m 18 24.2 1.65, m







24 29.7 1.83, m 25 29.7 1.82, m 25 29.7 1.81, m 26 29.7 1.83, m
25 74.9 5.53, m 26 74.9 5.53, m 26 74.9 5.54, m 27 74.9 5.54, m
AcO 169.7 * AcO 169.7 * AcO 169.7* AcO 169.7 *
26 80.7 4.03, m 27 80.8 4.03, m 27 80.7 4.03, m 28 80.8 4.05, m
27 30.9 1.79, m 28 30.9 1.79, m 28 39.1 1.16, m 29 30.9 1.80, m
28 32.0 1.23, m 29 32.0 1.23, m 29 28.2 1.51, m 30 32.0 1.25, m
29 22.8 1.28, m 30 22.8 1.28, m 30 22.8 0.85, d (6.0) 31 22.9 1.27, m
30 14.7 0.84, t (7.0) 31 14.2 0.86, t (6.5) 31 22.8 0.85, d (6.0) 32 14.2 0.86, t (6.6)









174.5 - 174.5 - 174.5 - 174.6 -
2’




52.7 5.74, q (7.3) 2’ 52.7 5.75, q (7.3)









28.9 3.14, s 28.9 3.13, s 28.9 3.14,s 28.9 3.15,s
4’
15.0 1.54, d (7.3) 4’ 15.0 1.55, d (7.3) 4’ 15.0 1.55, d (7.3)
4’
15.0 1.54, d (7.4)
16.0 1.60, d (7.2) 16.0 1.69, d (7.1) 16.0 1.60, d (7.3) 16.0 1.61, d (7.2)
a duplicated values correspond to the major syn and minor anti rotamers respectively; * Overlapped with
C-4 Glc3.
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Table 3. NMR data for the carbohydrate moieties of erylusamides A–D (1–4) in pyridine-d5.
Position
1 2 3 4
δ 13C δ 1H, m (J, Hz) δ 13C δ 1H, m (J, Hz) δ 13C δ 1H, m (J, Hz) δ 13C δ 1H, m (J, Hz)
Gal
1 104.4 5.16, d (7.5) 104.4 5.16, d (7.7) 104.4 5.15, d (7.6) 104.4 5.16, d (7.7)
2 70.7 4.54, m 70.7 4.53, m 70.7 4.53, m 70.72 4.53, m
3 84.4 4.24, m 84.3 4.25, m 84.3 4.25, m 84.32 4.24, m
4 69.0 4.70, brs 68.9 4.71, brs 68.7 4.71, brs 68.91 4.72, brs
5 77.3 4.21, m 77.4 4.20, m 77.3 4.21, m 77.27 4.20, m
6 61.6





(5.1; 10.6) (5.2; 10.6) (4.9; 10.9) (5.2; 10.6)
4.44, dd 4.43, dd 4.44, dd 4.44, dd
(6.8; 10.6) (6.9; 10.6) (6.7; 10.9) (6.9; 10.6)
Xyl
1 103.2 4.90,d (7.3) 103.2 4.89, d (7.3) 103.2 4.90, d (7.6) 103.2 4.90, d (7.4)
2 78.3 4.22, m 78.2 4.22, m 78.3 4.21, m 78.3 4.21, m
3 88.2 4.25, m 88.1 4.24, m 88.0 4.24, m 88.0 4.26, m









4.14, m 4.14, m 4.14, m 4.13, m
Glc1
1 104.6 4.86, d (7.9) 104.6 4.87, d (7.8) 104.6 4.88, d (8.0) 104.6 4.87, d (8.0)
2 74.9 3.97, m 74.6 3.96, m 74.6 3.97, m 74.6 3.98, m
3 76.6 4.18, m 76.6 4.18, m 76.6 4.18, m 76.6 4.18, m
4 81.9 3.97, m 81.8 3.97, m 81.9 3.97, m 81.9 3.97, m









5.16, m 5.14, m 5.16, m 5.15, m
Ac (C-6) 171.0 - - 171.0 171.0 -
Glc2
1 102.8 5.55, d (8.0) 102.8 5.55, d (8.2) 102.8 5.55, d (8.5) 102.8 5.55, d (8.1)
2
72.2 5.48, dd 72.2 5.47,dd 72.2 5.48, t 72.1 5.48, dd
(8.2; 9.5) (8.4; 9.3) (9.3) (8.4;9.3)
3 73.5 5.78, t (9.6) 73.5 5.78, t (9.6) 73.5 5.78, t (9.9) 73.4 5.78, t (9.5)
4 69.4 5.42, t (9.8) 69.4 5.42, t (9.7) 69.4 5.42, t (9.7) 69.4 5.42, t (9.7)
5 72.1 4.22, m 72.1 4.21, m 72.1 4.22, m 72.1 4.22, m
6
62.7 4.32, dd 62.7 4.32, dd 62.6 4.31, dd 62.7 4.31, dd
(2.3; 12.1) (2.1; 11.8) (~2; 11.8) (2.3;12.1)
4.51, dd 4.50,dd, 4.52, dd 4.51, dd
(5.4; 12.1) (5.3; 12.0) (4.8; 11.8) (5.4;12.1)
Ac (C-2) 170.2 - 170.2 - 170.2 - 170.2 -
Ac (C-3) 170.1 - 170.1 - 172.2 - 170.2 -
Ac (C4) 169.8 - 169.9 - 169.9 - 169.9 -
Ac (C-6) 170.4 - 170.5 - 170.5 - 170.5 -
Glc3
1 99.6 6.37, d (7.9) 99.6 6.35, d (8.0) 99.6 6.36, d (7.6) 99.6 6.36, d (7.9)
2 72.3 5.62, m 72.2 5.61, t (10) 72.2 5.62, m 72.2 5.62, m
3 73.7 5.90, t (9.4) 73.7 5.89, t (9.5) 73.7 5.9, t (9.3) 73.7 5.90, t (9.5)
4 69.7 5.58, m 69.7 5.56, m 69.7 5.56, m 69.7 5.56, m
5 72.3 3.93, m 72.2 3.92, m 72.2 3.92, m
6
62.5 4.19, m 62.5 4.56, m 62.4 4.19, m 62.4 4.18, m
4.57, m 4.18, m 4.56, m 4.57, m
Ac(C-2) 169.6 - 169.6 - 169.7 - 169.7 -
Ac(C-3) 170.5 - 170.5 - 170.5 - 170.5 -
Ac(C-4) 169.7 - 169.7 - 169.8 - 169.7 -
Ac(C-6) 170.2 - 170.4 - 170.4 - 170.4 -
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Figure 2. Key HMBC (red ash s) and HSQC-TOCSY (blue lines) correlations establishing the structure
of the aglycone moiety.
The presence of two vicinal oxymethine groups constituting an isolated stereocluster was the
most striking feature of the aglycone moiety. In the HSQC spectrum, the crosspeaks at δ 80.7/δ 4.03
and δ 74.9/δ 5.53 suggested the presence of two non-equivalent secondary O-substituted alcohols.
An HMBC cross-peak was observed between the proton at δ 4.03 and the carbon at δ 74.8 ppm.
However, no COSY correlation was observed between the two oxymethine signals suggesting that the
dihedral angle between the two protons should be around 90◦ [18]. These data were consistent with
a vicinal diol, with one hydroxyl group acylated and the other one linked to a sugar moiety [19,20].
Furthermore, a connection could be assigned between this diol moiety and ter inal n-butyl, as depicted
from the H2B crosspeak between C-26 (δ 80.7) and the proton at δ 1.79 ppm (H-27), as well as
HSQC-TOCSY long range correlations 30.9→ 32.0→ 22.8→ 14.7→ 0.84. The remaining deshielded
signal at δ 210.5 corresponded to an aliphatic symmetrical ketone, as deduced from the HMBC
correlation with two separated CH2 signals at δ 2.42 (4H) and 1.64 (4H) ppm. Compound 1 was
methanolysed to liberate the aglycone methyl ester (compound 5, Figure 3), which was further
converted in the corresponding acetonide, and their MS and NMR spectra (see Sections 3.4 and 3.7)
analysed and compared with those of compound 1. Compound 5 showed a molecular adduct ion
[M + Na]+ at m/z 620.5 (Figure 3) compatible with the methyl ester of the deacetylated free aglycone.
Comparison of this result with the ones obtained from MS analysis of compound 1 confirmed the
presence of an acetyl group on the aglycone moiety: the MS/ S data on molecular ion [M − H] at
m/z 1782.8 of compound 1 showed a fragment ion at m/z 624.5, due to the loss of the oligosaccharide
portion, compatible with an monoacetylated aglycone moiety. Additionally, a detailed analysis of
tandem ass spectrometry (ESI+-MS/MS) data (Figure 3) obtained on the aglycone methyl ester 5,
at m/z 620.5, suggested the location of the carbonyl function at C-16 in the aliphatic chain. In fact,
product ion spectra contained diagnostic ions at m/z 265.3 [C15H30O2 + Na]+ and 390.3 formally
arising from α-cleavage of the carbonyl group. Furthermore, a fragment ion at m/z 138.1 confirmed
the presence of the N-methylalanine moiety.
Finally, analysis of NMR spectra of the acetonide 6 (see Section 3.7) confirmed the occurrence and
relative stereochemistry of the 1,2 diol system: the two oxymethine protons at δ 3.72 and 3.74 were
coupled by H2BC to the downfield shifted carbons at δ 81.4 and 1.5, respectively, as well as by HMBC
with the oxygenated carbon signal at δ 107.8, bearing, in turn, the two acetonide methyl groups at
δ 1.50). According to the carbon chemical shifts of these methyl groups of 6, overlapping at 27.0 ppm,
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The aglycone part as described above accounted for four out of the 18 formal unsaturations
predicted by the molecular formula of 1. Thus, the remaining 14 double bond equivalents were
attributable to the glucosidic portion. The analysis of the 1H, 13C and HSQC spectra revealed five
anomeric carbons, accounting for five sugar rings. The remaining formal unsaturations were assigned
to nine acetate residues, which fulfilled the observed [M − H]− ion peak at m/z 1782.8345.
Hydrolysis of compound 1 showed that D-xylose, D-galactose and D-glucose were the only
monomers present with a ration 1:1:3. The sequence of these sugar residues was determined by
extensive NMR study, especially based on 2D techniques (COSY-45, HSQC, HSQC–TOCSY, H2BC,
HMBC and NOESY) (Table 2).
The five anomeric carbons and their attached protons were unequivocally identified at δ13 C/1H:
104.6/4.86 (d, J = 7.9 Hz); 104.4/5.16 (d, J = 7.5 Hz); 103.2/4.90 (d, J = 7.3 Hz); 102.8/5.55 (d, J = 8.0 Hz)
and 99.6/6.37 (d, J = 7.9 Hz) (Figure 4). The anomeric configurations were assigned as β from the
magnitude of the 3J1,2, values, all within the 7–9 Hz interval, typical of diaxial proton coupling [24].
Moreover, the 13C NMR shifts of the anomeric carbons, approximatively 100 ppm, also indicate that
the corresponding sugars are connected through β-glycosidic bonds [25,26].
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4.86 disclosed  the  linkage between  the aglycone portion and  the  first unit of  the pentasaccharide 
chain, which was assigned  to a monoacetylated glucose  residue  (Glc1).  In  fact,  starting  from  the   
anomeric  proton TOCSY  experiments  allowed  to delineate  the  entire  spin  system while  relative 
configuration was achieved by analysis of NOESY data and J couplings. Furthermore, H‐6 methylene 
resulted deshielded  thus  suggesting  the  first  acetylation  site.  The MS/MS  fragment  at m/z  828.5 
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Figure 4. Expansion of HSQC spectrum of erylusamide A (1) showing the anomeric carbon,
the oxymethines and oxymethylenes correlations.
Six of the oxymethines (δH 5.90, 5.78, 5.62, 5.58, 5.48 and 5.42) and three of the oxymethylenes
(δH 4.51/4.32, 4.57/4.19, 5.16/4.92) had proton resonating at 1–2 ppm downfield with respect to
free hydroxyl groups [19], which indicated the sites of acetylation (Figure 4). The position of acetyl
groups was ascertained by HMBC correlations between the acetyl carbonyls and the corresponding
oxymethine protons (Figure 5).
The long-range HMBC correlation between C-26 (δ 80.7 ppm) and the β-anomeric proton at δ 4.86
disclosed the linkage between the aglycone portion and the first unit of the pentasaccharide chain,
which was assigned to a monoacetylated glucose residue (Glc1). In fact, starting from the anomeric
proton TOCSY experiments allowed to delineate the entire spin system while relative configuration was
achieved by analysis of NOESY data and J couplings. Furthermore, H-6 methylene resulted deshielded
thus suggesting the first acetylation site. The MS/MS fragment at m/z 828.5 [aglyconeGlc1 − H]−)
from the ion [M − H]− at m/z 1782.8 is compatible with a monoacetylated glucose.
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1796.8434 respectively, consistent with  the empirical  formula C84H135NO40, suggesting an  isomeric 
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A  careful  comparison  of  NMR  spectra  indicated  structures  with  aglycones  closely  related  to 





1H  and  13C  NMR  spectra  of  compound  2  were  almost  superimposable  with  those  of  1, 
suggesting that the additional methylene should be positioned within the long hydrocarbon chain. 
Furthermore, NMR data showed that the only difference between the isomeric compounds 2 and 3 
was at one chain end of  the aglycone moiety, where an  isobutyl group  in 3 replaced  the  terminal 
n‐butyl residue of 2. In fact, the 1H NMR spectrum of 3 showed the presence of a doublet at δ 0.85 
ppm  (6 H,  J =  6.0 Hz)  and  a multiplet  signal  at  δ  1.51  assigned,  respectively,  to  the methyl  and 
methine  protons  of  the  isobutyl  moiety.  The  signal  at  δ  1.16  was  attributed  to  the  remaining 
Figure 5. Expansion of H BC spectru showing correlations to acetate carbonyls in sugar oiety.
The HMBC cross peak between C-4 Glc1 and the anomeric proton at 4.90 identified the glycosidic
bond between this glucose and the xylose residue, confirmed by the correlation between C-1 Xyl and
H-4 Glc1. Xylose showed another glycosidic bond with another glucose residue, which was depicted
from cross peaks C-2 Xyl/H-1 Glc3 and C-1 Glc3/H-2 Xyl. A third β-glycosidic bond between xylose
and a galactose residue was apparent from the long range correlation C-3 Xyl/ H-1 Gal and the NOESY
correlation H-3 Xyl/H-1Gal. Finally, the galactose residue was connected to another glucose unit
through the cross peak between C-3 Gal and H-1 Glc2 (Figure 6).
HR-ESI-MS of erylusamides B (2) and C (3) showed [M−H]− ions at m/z 1796.8515 and 1796.8434
respectively, consistent with the empirical formula C84H135NO40, suggesting an isomeric relationship,
which was reflected in a different behaviour of the two metabolites in HPLC analysis. A careful
comparison of NMR spectra indicated structures with aglycones closely related to erylusamide A,
which differed for an extra methylene, also confirmed by the peak at m/z 638.5 [aglycone − H]−
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In fact, the 1H NMR spectrum of 3 showed the presence of a doublet at δ 0.85 ppm (6 H, J = 6.0 Hz) and
a multiplet signal at δ 1.51 assigned, respectively, to the methyl and methine protons of the isobutyl
moiety. The signal at δ 1.16 was attributed to the remaining methylene group. The two equivalent
methyl carbons of the isobutyl moiety were observed at δ 22.8 ppm, while the methine carbon and the
methylene appeared, respectively, at δ 28.2 and δ 39.1 ppm.
Erylusamide D (4) had a molecular formula of C85H136O40N as revealed by HR-MS-ESI [M − H]−
molecular ion peak at 1810.8644. NMR spectra of 4 and 1 were almost superimposable, the only
difference being, as for compound 2, the length of the hydrocarbon chain that has two extra methylene
groups, confirmed by the presence, in the ESI−-MS/MS spectrum, of the fragment at m/z 652.5
[aglycone − H]− (C38H70O7N).
In conclusion, the bioassay guided fractionation of the dichloromethane extract of the marine
sponge Erylus cf. deficiens afforded a glycolipid fraction showing IDO inhibitory activity, from which
were isolated four new polyketide glycosides structurally related to erylusamines reported in congener
sponges [6–8]. The identification of the glycolipid content of sponges is important, not only due to
the bioactivity that they usually display, but also because they have become useful markers in the
taxonomic classification.
3. Materials and Methods
3.1. General Experimental Procedures
NMR spectra were acquired on a Bruker DRX-600 apparatus (Bruker BioSpin GmbH, Rheinstetten,
Germany) operating at 600 for 1H and 150 MHz for 13C). Chemical shifts were expressed as δ values and
reported to the residual solvent signals (pyridine-d5, δH = 8.73, 7.58 and 7.21; δC = 149.9, 135.5 and 123.5);
coupling constants were reported in units of Hertz (Hz). HR-ESI-MS analysis was run on a Q-Exactive
mass spectrometer (Thermo Fisher Scientific, Rockford, IL, USA). ESI-MS/MS spectra were achieved
on a Q-Tof micro mass spectrometer (Waters, Milford, MA, USA). GC-MS analysis were performed on
a Shimadzu GCMS-QP 2010Plus (Kyoto, Japan) using a Teknokroma TRB-1 column (30 m × 0.25 µm)
(Barcelone, Spain).
IR spectra were obtained using a Mattson Satellite FT-IR (Waltham, MA, USA) and only the
diagnostic absorption bands are reported, in cm−1. Flash column chromatography was performed
on reversed-phase silica gel LiChroprep® RP-18 40–63 µm (Merck Ref. 113900, Darmstadt, Germany).
Thin layer chromatography was performed on silica gel 60 F254 aluminum sheets (Merck Ref. 5554)
and visualized with UV light (254 nm) and vanillin/sulfuric reagent (0.5 g vanillin in sulfuric/MeOH
4:1 v/v) followed by heating up to 120 ◦C.
HPLC separations were performed on an Ultimate 3000 Dionex liquid chromatograph (Germering,
Germany) equipped with a Phenomenex Luna 2.6 µ phenyl-hexyl column 100 Å (150 mm × 4.60 mm)
(Torrance, LA, USA).
All solvents and reagents were obtained from commercial suppliers and were used without
further purification.
3.2. Biological Material
A specimen of Erylus cf. deficiens Topsent, 1927 (Demospongiae, Tetractinellida, Geodiidae) was
collected by scuba diving on the Gorringe Bank, a seamount located 150 km off the southwest coast
of Portugal, at a depth between 40 and 50 m, and kept at −20 ◦C until processed. Identification was
performed through analyses of the skeletal characters (spicules) under optical microscopy. A voucher
sample was preserved in 90% ethanol and deposited in the Biology Department’s zoological collection
of the University of the Azores, Ponta Delgada, Portugal (collection DBUA.Por).
Mar. Drugs 2016, 14, 179 11 of 14
3.3. Extraction and Isolation Procedures
The lyophilized specimens (63 g) were triturated in a grinder and extracted with methanol
at room temperature for 24 h, yielding 7.2 g of crude extract after solvent evaporation under
vacuum. This methanol extract was subsequently re-extracted with dichloromethane for 24 h, at room
temperature, affording 1.8 g of extract. An aliquot of the dichlorometane extract (0.958 g) was coarse
fractionated by RP-C18 flash chromatography with an eluent gradient of decreasing polarity from
methanol to dichloromethane/methanol 9:1, in a total of 11 fractions. The more active fraction in the
bioassay (fraction 2, 150 mg, eluent: methanol) was fractionated by HPLC using a column Phenomenex
Luna 2.6 µ phenyl-hexyl 100 Å (150 mm × 4.60 mm) and a gradient of MeOH/0.1%TFA in H2O (flow
0.75 mL·min−1 from 80:20 to 100% MeOH). Erylusamides A–D (compounds 1–4) were obtained by
injection of more than two hundred 10 µL samples and pooling homologues fractions. Erylusamide
A: (RT: 27.71 min, 27.7mg), Erylusamide B: (RT: 29.10 min; 23.0 mg), Erylusamide C: (RT: 30.74 min;
17.9 mg) and Erylusamide D: (RT: 33.41 min; 8.7 mg).
Erylusamide A (1): Colorless oil; 1H and 13C NMR data, see Tables 2 and 3; HR-ESIMS m/z
1782.8345 [M − H]− (calcd for C83H132O40N, 1782.8325); ESI-MS/MS m/z 828.5 [aglyconeGlc1 − H]−
(C44H78O13N), 624.5 [aglycone − H]− (C36H66O7N).
Erylusamide B (2): Colorless oil; 1H and 13C NMR data, see Tables 2 and 3; HR-ESIMS m/z
1796.8515 [M − H]− (calcd for C84H134O40N, 1796.8482). ESI-MS/MS m/z 842.6 [aglyconeGlc1 − H]−
(C45H80O13N), 638.5 [aglycone − H]− (C37H68O7N).
Erylusamide C (3): Colorless oil; 1H and 13C NMR data, see Tables 2 and 3; HR-ESIMS m/z
1796.8434 [M − H]− (calcd for C84H134O40N, 1796.8482). ESI-MS/MS m/z 842.6 [aglyconeGlc1 − H]−
(C45H80O13N), 638.5 [aglycone − H]− (C37H68O7N).
Erylusamide D (4): Colorless oil; 1H and 13C NMR data, see Tables 2 and 3; HR-ESIMS m/z
1810.8644 [M − H]− (calcd for C85H136O40N, 1810.8638). ESI-MS/MS m/z 856.6 [aglyconeGlc1 − H]−
(C46H82O13N), 652.5 [aglycone − H]− (C38H70O7N).
3.4. Methanolysis of Crude Fraction of Glycolipids
A portion of the crude fraction of glycolipids (12.9 mg) was dissolved in 1.5 mL of 2 M HCl in
MeOH. The reaction mixture was stirred at 80 ◦C with refluxing for 4.5 h and, after cooling, neutralized
with 5% ammonium hydroxide aqueous solution and finally evaporated to dryness under vacuum.
The residue was partitioned between H2O and dichloromethane (2 mL × 3). Both phases were
evaporated. The aglycone went into the organic phase and the methyl glycosides into the aqueous one.
Aglycone methyl ester (compound 5, major/*minor rotamer):
1H NMR (pyridine-d5, 600 MHz): δ 5.38/4.93* (1H, q, J = 7.3Hz, H-2′); 3.96 (1H, m, H-26); 3.97 (1H,
m, H-25); 3.63/3.67* (3H, s, CH3O); 2.94/2.97* (3H, s, H-3′); 2.40 (4H, m, H-15/H-17); 2.38 (2H, m,
H-2); 1.88 (2H, m, H-23); 1.87 (2H, m, H-27); 1.77 (2H, m, H-3);1.60 (4H, m, H-14/H-18); 1.62 (2H, m,
H-28); 1.41/1.46* (3H, d, J = 7.3Hz, H-4′); 1.32 (2H, m, H-29); 1.36 (2H, m, H-4); 1.28 (2H, m, H-13); 1.26
(24H, m); 0.85 (3H, t, J = 7.1Hz, H-30). 13C NMR (pyridine-d5, 150 MHz): δ 210.5 (C, C-16); 173.1/172.9*
(C, C-1); 172.8/172.3* (C, C-1′); 75.2 (CH, C-26); 75.0 (CH, C-25); 53.2/55.6* (CH, C-2′); 51.3/52.2* (CH3,
CH3O); 43.0 (CH2, C-15/C-17); 34.0 (CH2, C-2); 33.8 (CH2, C-24/C-27); 32.6 (CH2, C-28); 32.1/29.0*
(CH3, C-3′); 29.6 (CH2, C-4/C-13); 27.1 (CH2, C-23); 25.4 (CH2, C-3); 24.3 (CH2, C-14/C-18); 23.1
(CH2, C-29); 15.0/15.9* (CH3, C-4′); 14.6 (CH3, C-30). HR-ESIMS m/z 620.4856 [M + Na]+ (calcd. for
C35H67O6NNa, 620.4866). ESI-MS/MS m/z 620.5 [M + Na]+, 560.6, 503.5, 390.3, 265.3, 138.1.
3.5. Derivatization of Glycosides
The methyl glycosides were dissolved in 0.5 mL of pyridine and 36 µL of trimethylsilyl chloride
(TMSCl) and 106 µL of hexamethyldisiloxane (HMDS) were added to the mixture. The reaction mixture
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was stirred at 60 ◦C for 2 h and evaporated to dryness. The residue was partitioned between H2O
and dichloromethane (3 × 1 mL). The TMS-glycosides went into the organic phase and evaporated
to dryness.
3.6. Preparation of Monosaccharide Standards
Commercial D-glucose, D-galactose and D-xylose were dissolved in 2 M HCl in MeOH and stirred
with refluxing at 80 ◦C for 2 h. Thereafter, methanol and HCI were removed under a nitrogen stream
without prior neutralization. An excess of TMSCl and HMDS were added to the dried material.
The solutions were then heated at 60 ◦C for 2 h. The derivatized samples were evaporated under
vacuum and used as standards for GC analysis
3.7. Synthesis of the Acetonide of Compound 5
Compound 5 (0.77 mg, 1.2 µmol) was dissolved in dimethoxypropane (500 µL) with a catalytic
amount of pyridinium p-toluenesulfonate (PPTS). The reaction mixture was heated at 60 ◦C for 5 h,
then allowed to cool at room temperature and partitioned between water and Et2O (4 × 5 mL).
The organic phase was evaporated to dryness under nitrogen stream affording compound 6 (0.8 mg,
1.2 µmol).
Acetonide of compound 5:
1H NMR (pyridine-d5, 600 MHz): δ 5.37 (1H, q, J = 7.3Hz, H-2′); 3.74 (1H, m, H-26*); 3.72 (1H, m,
H-25*); 3.62 (3H, s, OCH3); 2.94 (3H, s, H-3′); 2.43 (4H, m, H-15/H-17); 2.38 (2H, m, H-2); 1.65 (4H,
m, H-14,/H-18); 1.51 (6H, s, acetonide α and β CH3); 1.41 (3H, d, J = 7.3Hz, H-4′); 1.36 (2H, m, H-4);
1.30 (2H, m, H-29); 1.28 (2H, m, H-13); 0.88 (3H, t, J = 7.3Hz, H-30). 13C NMR (pyridine-d5, 150 MHz):
δ 210.6 (C, C-16); (173.2 (C, C-1); 172.7 (C, C-1′); 107.8 (C, acetonide OCO); 81.5 (CH, C-25*); 81.4 (CH,
C-26*); 53.0 (CH, C-2′); 51.9 (OCH3); 42.7 (CH2, C-15/C-17); 33.3 (CH2, C-27); 31.9 (CH3, C-1′); 29.6
(CH2, C-4); 29.5 (CH2, C-13); 28.8 (CH2, C-28); 27.7 (acetonide CH3); 25.4 (CH2, C-3); 24.2 (CH2, C-14/
C-18); 23.0 (CH2, C-29); 14.6 (CH3, C4′) 14.2 (CH3, C-30).
3.8. Bioassay Description (GPSD2 Screening Application) [15]
Modified yeast cells from overnight growth are re-inoculated at OD 0.1 in selective medium
to induce specific toxicity conditions and are dispensed automatically by a JANUS® Automated
Workstation (Perkin Elmer, Waltham, MA, USA) into a 96-well plate at a final volume of 200 µL.
In addition, 4 µL of organic and aqueous extracts (resuspended in dimethyl sulfoxide at a final
concentration of 25 mg dry extract/mL) are added to 200 µL yeast cells, previously dispensed. One well
is not exposed to any extract as control. Plates are incubated for 3 days. Absorbance and fluorescence
signal were measured constantly every 2.5 h.
3.9. COS-7 Cells Bioassay [15]
COS-7 cells were grown in Dulbecco’s modified eagle medium (DMEM) 1000 mg/mL glucose,
with GlutaMAX and pyruvate (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine
serum (FBS) and 1% non-essential amino acids (NEAA). Cells were maintained at 80%–90% confluence
at 37 ◦C and 5% CO2. COS-7 cells in 24-well plates were transiently transfected with pCDNA3-IDO
using FuGene HD (Roche Diagnostics, Basel, Switzerland) following manufacturer’s instructions.
In addition, 3 h post-transfection, 5 µL of samples’ stock solutions and 0.1× diluted solutions were
added to cells and incubated for 24 h. Transfection efficiency after 24 h of extract exposure was assessed
by direct observation of enhanced green fluorescent protein (EGFP) signal, using an inverted Carl Zeiss
microscope AxioObserver D1 (Exc = 485/20 nm, Em = 515 nm) (Oberkochen, Germany). The IDO
activity was evaluated by measuring kynurenine concentration in the supernatant by HPLC. Briefly,
supernatants from cell culture were collected and immediately frozen at −20 ◦C until analysis. Protein
precipitation and kynurenine extraction was performed by addition of trichloroacetic acid (TCA) at a
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final concentration of 6%. After discarding cell debris by centrifugation, supernatants were injected
into the HPLC pump (Model LC-6A, Shimadzu Corporation, Kyoto, Japan). Separation was performed
using a reversed-phase cartridge Aquasil RP18 column (200 mm length, 4.6 µm grain size) from
Thermo Scientific (Rockford, IL, USA). An SPD-6AU UV-VIS spectrophotometric detector (Shimadzu
Corporation, Kyoto, Japan) in a flow stream series connection was used for detection of kynurenine at
a wavelength of 360 nm. The elution buffer consisted of a degassed potassium phosphate solution
(0.015 mol/L, pH 6.4) containing 27 mL/L acetonitrile. Analysis was carried out at room temperature
at a flow rate of 1.2 mL/min.
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